This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Feb 14;42(7):758-760.

doi: 10.1093/eurheartj/ehaa971.

On cerebrotoxicity of antihypertensive therapy and risk factor cosmetics

Franz H Messerli^{1

2

3}, Chirag Bavishi⁴, Adrian W Messerli⁵, George C M Siontis¹

Affiliations

Affiliations

¹ Department of Cardiology, Bern University Hospital, University of Bern, Switzerland.
² Jagiellonian University, Krakow, Poland.
³ Division of Cardiology, Mount Sinai Health Medical Center, Icahn School of Medicine, New York, NU, USA.
⁴ Lifespan Cardiovascular Institute, Warren Alpert Medical School at Brown University, Providence, RI, USA.
⁵ Gill Heart and Vascular Institute, University of Kentucky, Lexington, KY, USA.

PMID: 33369623
DOI: 10.1093/eurheartj/ehaa971

Editorial

On cerebrotoxicity of antihypertensive therapy and risk factor cosmetics

Franz H Messerli et al. Eur Heart J. 2021.

. 2021 Feb 14;42(7):758-760.

doi: 10.1093/eurheartj/ehaa971.

Authors

Franz H Messerli^{1

2

3}, Chirag Bavishi⁴, Adrian W Messerli⁵, George C M Siontis¹

Affiliations

¹ Department of Cardiology, Bern University Hospital, University of Bern, Switzerland.
² Jagiellonian University, Krakow, Poland.
³ Division of Cardiology, Mount Sinai Health Medical Center, Icahn School of Medicine, New York, NU, USA.
⁴ Lifespan Cardiovascular Institute, Warren Alpert Medical School at Brown University, Providence, RI, USA.
⁵ Gill Heart and Vascular Institute, University of Kentucky, Lexington, KY, USA.

PMID: 33369623
DOI: 10.1093/eurheartj/ehaa971

No abstract available

PubMed Disclaimer

Comment in

Cerebrotoxicity of antihypertensive therapy in the UK Biobank Cohort Study.
Messerli FH, Bavishi C, Messerli AW, Siontis GCM. Messerli FH, et al. Eur Heart J. 2021 Nov 1;42(41):4282. doi: 10.1093/eurheartj/ehab567. Eur Heart J. 2021. PMID: 34480536 No abstract available.
Big cohort studies offer insights into preventable risk factors.
Wartolowska KA, Webb AJS. Wartolowska KA, et al. Eur Heart J. 2021 Nov 1;42(41):4280-4281. doi: 10.1093/eurheartj/ehab566. Eur Heart J. 2021. PMID: 34480539 Free PMC article. No abstract available.
How to identify which patients should not have a systolic blood pressure target of <120 mmHg.
Spence JD, Müller LO, Blanco PJ. Spence JD, et al. Eur Heart J. 2022 Feb 10;43(6):538-539. doi: 10.1093/eurheartj/ehab552. Eur Heart J. 2022. PMID: 34508627 No abstract available.
Importance of pulse pressure at low systolic blood pressure.
Messerli FH, Siontis GCM, Bavishi C, Messerli AW. Messerli FH, et al. Eur Heart J. 2022 Feb 10;43(6):540. doi: 10.1093/eurheartj/ehab553. Eur Heart J. 2022. PMID: 34508628 No abstract available.

Comment on

Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study.
Wartolowska KA, Webb AJS. Wartolowska KA, et al. Eur Heart J. 2021 Feb 14;42(7):750-757. doi: 10.1093/eurheartj/ehaa756. Eur Heart J. 2021. PMID: 33238300 Free PMC article.

Similar articles

Cerebrotoxicity of antihypertensive therapy in the UK Biobank Cohort Study.
Messerli FH, Bavishi C, Messerli AW, Siontis GCM. Messerli FH, et al. Eur Heart J. 2021 Nov 1;42(41):4282. doi: 10.1093/eurheartj/ehab567. Eur Heart J. 2021. PMID: 34480536 No abstract available.
Evaluating Metabolic Risk Factors That Affect Brain Structure.
Caspers S. Caspers S. Radiology. 2019 Jun;291(3):772-773. doi: 10.1148/radiol.2019190672. Epub 2019 Apr 23. Radiology. 2019. PMID: 31013188 No abstract available.
Heretical report on the efficacy of blood pressure treatment in a population setting.
Lund-Johansen P. Lund-Johansen P. Cardiovasc Drugs Ther. 1995 Jun;9(3):373-4. doi: 10.1007/BF00879025. Cardiovasc Drugs Ther. 1995. PMID: 8527347 No abstract available.
Auch isolierter diastolischer Bluthochdruck ist ein Gefäßrisiko.
Zidek W. Zidek W. MMW Fortschr Med. 2020 Nov;162(20):32. doi: 10.1007/s15006-020-4602-6. MMW Fortschr Med. 2020. PMID: 33219958 Review. German. No abstract available.
Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
Chrysant SG, Germino FW, Neutel JM. Chrysant SG, et al. Am J Cardiovasc Drugs. 2012 Dec 1;12(6):375-89. doi: 10.1007/BF03262472. Am J Cardiovasc Drugs. 2012. PMID: 23116225 Review.

See all similar articles

Cited by

The relationship between isolated hypertension with brain volumes in UK Biobank.
Newby D, Winchester L, Sproviero W, Fernandes M, Ghose U, Lyall D, Launer LJ, Nevado-Holgado AJ. Newby D, et al. Brain Behav. 2022 May;12(5):e2525. doi: 10.1002/brb3.2525. Epub 2022 Apr 1. Brain Behav. 2022. PMID: 35362209 Free PMC article.
Big cohort studies offer insights into preventable risk factors.
Wartolowska KA, Webb AJS. Wartolowska KA, et al. Eur Heart J. 2021 Nov 1;42(41):4280-4281. doi: 10.1093/eurheartj/ehab566. Eur Heart J. 2021. PMID: 34480539 Free PMC article. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information